GL1X · GenesisL1 explorer

MolNFT v1 · #81399 · protein

Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors

3UPH · RNA-directed RNA polymerase: “Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase inhibitors”. X-ray diffraction, 2 ligands (0C1, PO4), 15 pockets (best druggability 0.81). MolNFT v1 #81399 on…

PDB
3UPH
Type
protein
Length
1,121 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
RNA-directed RNA polymerase
EC
2.7.7.48
UniProt
O92972
Ligands
0C1, PO4
Pockets
15 · best druggability 0.81

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARNA-directed RNA polymerase (EC 2.7.7.48)protein56348% helix, 15% strandO92972
BRNA-directed RNA polymerase (EC 2.7.7.48)protein55848% helix, 15% strandO92972

Ligands and binding sites

  • 0C1 · 6-(2,5-difluorobenzyl)-N-(methylsulfonyl)-8-(2-oxo-1,2-dihydropyridin-3-yl)-3,6-dihydro-2H-furo[2,3-e]indole-7-carboxamide · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111540.810.82880C1
211560.800.82860C1
31680.530.7925empty
41020.500.8121empty
51980.460.7429empty

Interfaces

1 interface between chains.

  • A–B · 1011 Ų buried · 13 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 disulfide (disulfide).

Compared structures

  • 3UPH · Synthesis of novel 4,5-dihydrofurano indoles and their evaluation as HCV NS5B polymerase… · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.